BioSyent Inc. (TSXV:RX)
Canada · Delayed Price · Currency is CAD 13.85
+0.15 (1.09%)
Jun 8, 2026, 3:59 PM EST
BioSyent Cash Flow Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 9.04 | 9.01 | 7.27 | 6.46 | 5.46 | 6.28 |
Depreciation & Amortization | 1.13 | 0.85 | 0.59 | 0.46 | 0.45 | 0.46 |
Stock-Based Compensation | 0.62 | 0.62 | 0.55 | 0.51 | 0.44 | 0.33 |
Other Adjustments | -0.77 | -0.57 | -0.64 | -0.92 | -0.31 | -0.22 |
Change in Receivables | 0.46 | -1.45 | 0.4 | 0.24 | -0.43 | -0.96 |
Changes in Inventories | -0.55 | -1.24 | 0.57 | -1.48 | -2.44 | -0.13 |
Changes in Accounts Payable | 1.51 | 2.15 | -1.08 | 0.01 | 1.5 | -0.16 |
Changes in Income Taxes Payable | 0.46 | 0.01 | 0.29 | -0.21 | 0.22 | -0.15 |
Changes in Unearned Revenue | 0.7 | -0.39 | 0.68 | -0.03 | -0.15 | -0.62 |
Changes in Other Operating Activities | -0.27 | 0.01 | 0.04 | 0.01 | 0.2 | -0.15 |
Operating Cash Flow | 12.45 | 9.01 | 8.66 | 5.05 | 4.95 | 4.67 |
Operating Cash Flow Growth | 78.11% | 3.99% | 71.39% | 2.15% | 5.86% | -32.19% |
Capital Expenditures | -0.06 | -0.05 | -0.04 | -0.06 | -0.05 | -0.08 |
Purchases of Intangible Assets | -0.27 | -0.34 | -4.63 | -0.11 | -0.47 | -0.01 |
Payments for Business Acquisitions | -22.16 | - | - | - | - | - |
Other Investing Activities | 6.17 | 4.48 | 7.96 | 1.06 | -10.27 | -4.74 |
Investing Cash Flow | -16.32 | 4.09 | 3.29 | 0.88 | -10.79 | -4.84 |
Short-Term Debt Issued | 8 | - | - | - | - | - |
Short-Term Debt Repaid | -4 | - | - | - | - | - |
Net Short-Term Debt Issued (Repaid) | 4 | - | - | - | - | - |
Issuance of Common Stock | 0.07 | 0.1 | 0.25 | 0.07 | 0.04 | 0.01 |
Repurchase of Common Stock | -1.93 | -1.01 | -5.76 | -3.7 | -3.69 | -1.85 |
Net Common Stock Issued (Repurchased) | -1.87 | -0.91 | -5.51 | -3.63 | -3.65 | -1.84 |
Common Dividends Paid | -2.31 | -2.25 | -2.08 | -1.91 | -0.48 | - |
Other Financing Activities | -0.29 | -0.25 | -0.24 | -0.24 | -0.24 | -0.24 |
Financing Cash Flow | -0.46 | -3.41 | -7.83 | -5.78 | -4.37 | -2.08 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.03 | -0.01 | 0.01 | -0.03 | 0.04 | -0.02 |
Net Cash Flow | -4.3 | 9.68 | 4.13 | 0.12 | -10.17 | -2.26 |
Free Cash Flow | 12.39 | 8.96 | 8.62 | 5 | 4.9 | 4.59 |
Free Cash Flow Growth | 38.33% | 3.87% | 72.58% | 1.91% | 6.79% | -33.29% |
FCF Margin | 26.94% | 20.80% | 24.61% | 15.81% | 17.55% | 16.04% |
Free Cash Flow Per Share | 1.07 | 0.78 | 0.73 | 0.41 | 0.39 | 0.36 |
Levered Free Cash Flow | 15.95 | 10.35 | 8.31 | 5.16 | 5.2 | 5.44 |
Unlevered Free Cash Flow | 10.89 | 9.73 | 7.55 | 4.36 | 4.87 | 5.3 |